secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001193125-26-068512
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes: FY2025 revenue $1.48B, GAAP EPS $1.43; 2026 guidance shows net loss from Avadel deal
--------------------------------------------------------------------------------

- Total revenue $1.48B in 2025; proprietary net sales up ~9% to $1.18B; LYBALVI grew 22% in Q4.
- GAAP net income $242M ($1.43 dil EPS) vs $367M in 2024; Q4 net income $49.3M.
- Closed Avadel acquisition Feb 12, 2026; used $775M cash + $1.525B term loans; expects ~$150M inventory step-up expense.
- 2026 guidance: revenue $1.73-1.84B, GAAP net loss $(115)-$(135)M, adjusted EBITDA $370-410M.
- Alixorexton Phase 3 for narcolepsy to start Q1 2026; advancing orexin pipeline for ADHD and fatigue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000119312526068512/0001193125-26-068512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000119312526068512/alks-20260225.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-068512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer